Information från årsstämman den 27 maj 2020

IDL Biotech AB (publ) avhöll årsstämma på onsdagen den 27 maj 2020.

Annual meeting/Årsstämma

Årsstämma hålls den 27 maj 2020 kl. 15.00 på Piperska Muren, Scheelegatan 14, 112 28 Stockholm.

IDL Biotech signs new distribution agreement with Beckman Coulter, which gives the distributor global sales rights for the company's tumor markers on the ELISA manual platform.

Beckman Coulter has been one of IDL Biotech's most successful tumor markers distributors, and has sold the products in the Czech Republic and Slovakia for many years. With Beckman Coulter now taking over the global distribution rights for the company's tumor markers, we can intensify our focus on rapid testing and automation. At the same time, it gives Beckman Coulter the opportunity to broaden his product portfolio within tumor markers, ”says Charlotte Berg, CEO of IDL Biotech. IDL Biotech will continue to produce the tumor markers. The agreement is global, excluding the Chinese market.

Ombokning av engångsintäkt

I samband med revisionen av räkenskapsåret 2019 har IDL ombokat den engångsintäkt bolaget erhöll i samband med byte av distributör i Indonesien från nettoomsättning till övrig rörelseintäkt.

IDL Biotech signs distributor agreement in Zimbabwe

IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with PHM Diagnostic Lab Ltd in Zimbabwe.

Registration of TUBEX TF approved in Indonesia

The registration of TUBEX TF has been approved in Indonesia.

Distribution agreement signed in Malaysia

IDL has signed a distribution agreement in Malaysia

Meta analysis on TUBEX

Achieving accurate laboratory diagnosis of typhoid fever: a review and meta-analysis of TUBEX® TF clinical performance.

IDL signs distribution agreement in Uganda

IDL has signed a new distribution agreement in Uganda

Flaggningsmeddelande

Adma Förvaltnings AB ökar sitt innehav i IDL Biotech AB (publ)

IDL Biotech har tecknat avtal för automatisering av tumörmarkören TPS®

Kina har i många år varit ledande i användningen av tumörmarkörer. IDL Biotech har nu tecknat avtal med det kinesiska företaget ZECEN Biotech som avser en automatisering av analysprocessen för tumörmarkören TPS® på ZECEN Biotechs instrument. TPS® är en tumörmarkör som används framförallt vid bröst-, äggstocks- och prostatacancer.

IDL signed two new distributions agreements

IDL has signed two new distributions agreements.

IDL Biotech senarelägger delårsrapport till 22 oktober

Styrelsen i IDL Biotech AB (publ) har den 17 oktober beslutat att senarelägga publiceringen av bolagets delårsrapport för det tredje kvartalet 2019.

IDL Biotech knyter till sig världskänd Vetenskaplig Rådgivare

IDL Biotech fortsätter förstärka sitt globala team. Sam Kariuki, med över trettio års erfarenhet inom tropisk medicin, är ny Vetenskaplig Rådgivare till bolaget.

IDL Biotech AB har haft uppföljningsmöte med FDA

I juli lämnade IDL Biotech in underlag, så kallad Pre-submission request, till amerikanska FDA (Food and Drug Administration) för att kunna få ett framtida godkännande för försäljning i USA av UBC® Rapid, bolagets snabbtest för blåscancer. Idag genomfördes det första uppföljningsmötet med FDA.

IDL Biotech AB continues preparations to introduce its rapid test for bladder cancer, UBC Rapid, in the US.

IDL Biotech has started the work on mapping the US market.

IDL Biotech launches TUBEX TF in Kenya

On September 17, 2019, IDL Biotech will launch the company's rapid test for typhoid fever, TUBEX TF, in Kenya.

Jerker Swanstein new Chairman of the Board of Directors

The annual general meeting, held 28th of May 2019, re-elected Jerker Swanstein, Per-Anders Abrahamsson and Carsten Olsson, and elected Malin Ruijsenaars and Eva Sjökvist Saers as new members of the Board of Directors. During the statutory meeting held 28th of May 2019 Jerker Swanstein was selected as new Chairman of the Board of Directors.

Information from the Annual General Meeting

The Annual General meeting was held on the 28th of May 2019.

Notice of Annual General Meeting 2019

The shareholders of IDL Biotech AB (publ) are hereby invited to the Annual General Meeting on Tuesday, 28 May 2019, 15.00 at Redeye AB, Mäster Samuelsgatan 42, 10387 Stockholm.

IDL in the Spotlight

Spotlight has produced a short film about IDL Biotech.

SvD Börspluspod

CEO Charlotte Berg is interviewed in the latest podcast from SvD Börspluspod.

Interview with CEO Charlotte Berg

Börshajen has published an interview with Charlotte Berg, CEO at IDL Biotech.

Nomination Committe for IDL appointed

IDL Biotechs extra ordinary general meeting held on the 25th October 2018 decided to establish a nomination committee.

Interview with Charlotte Berg

On Saturday the 17th of November, the Swedish newspaper SvD, had an interview with the CEO, Charlotte Berg.

IDL Biotech AB offentliggör prospekt för beslutad företrädesemission

Styrelsen i IDL Biotech AB (Publ) har upprättat ett prospekt med anledning av den förestående nyemissionen med företrädesrätt för IDL Biotechs aktieägare. Prospektet har idag godkänts och registrerats av Finansinspektionen.

Information from Extraordinary General Meeting

The Extraordinary meeting was held on 2018-10-26.

Redeye Life Science Day

IDL Biotech will attend Redeye Life Science Day on November 21, at Haymarket City Scandic Stockholm, Hötorget 13-15, Stockholm. Charlotte Berg, CEO, will have her presentation at 1 pm. The presentation is live on www.redeye.se/live/lsday-2018. You can follow the presentation through the computer or cellphone.

Notice of Extra Annual General Meeting

The Extra Annual General Meeting will be held 25th of October.

New Share Issue

The board of directors of IDL Biotech AB (publ) has resolved to make a new share issue of approximately SEK 39,4 million before issue costs.

IDL Biotech second quarter report 2018

Information from the annual general meeting

IDL Biotech first quarter report 2018

Year-end report 2017

IDL Biotech third quarter report 2017

IDL Biotech second quarter report 2017

IDL Biotech first quarter report 2017

Year-end report 2016

More financial reports